文献速递冠心病外科瓣膜外科

冠状动脉旁路移植术后二级预防药物依从性的回顾性研究

A retrospective study on adherence to secondary prevention medications after coronary bypass surgery.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

这项全国性回顾性队列研究纳入2007年5月22日至2018年12月20日在Landspitali-国立大学医院接受冠状动脉旁路移植术的1536例患者,评估他汀类、β受体阻滞剂和肾素-血管紧张素系统(RAS)抑制剂的依从性及相关因素。结果显示严格依从比例分别为39.2%、36.9%和30.1%,不依从比例分别为14.4%、25.9%和43.6%;高衰弱风险评分、合并主动脉瓣置换及术后新处方与不依从相关。作者认为术后不依从常见,衰弱负担高和未用过冠心病药物治疗的患者应作为提高依从性的目标人群。

要点

  • 他汀类、β受体阻滞剂和RAS抑制剂的严格依从比例分别为39.2%、36.9%和30.1%。
  • 他汀类、β受体阻滞剂和RAS抑制剂的不依从比例分别为14.4%、25.9%和43.6%。
  • 高衰弱风险评分、合并主动脉瓣置换及术后新处方与不依从相关。

核心结论

  • 冠状动脉旁路移植术后药物治疗不依从常见,衰弱负担高和未用过冠心病药物治疗的患者应作为提高依从性的目标人群。

研究设计与样本

  • 全国性回顾性队列研究,纳入2007年5月22日至2018年12月20日在Landspitali-国立大学医院接受冠状动脉旁路移植术的全部个体(n=1536)。
  • 处方配药数据来自国家处方药物登记处,依从性以出院后至2年的覆盖天数比例估算,严格依从和不依从的切点分别为超过80%和低于50%。
  • 采用多变量logistic回归评估与不依从相关的变量。

主要发现

  • 他汀类、β受体阻滞剂和RAS抑制剂的严格依从比例分别为39.2%、36.9%和30.1%。
  • 他汀类、β受体阻滞剂和RAS抑制剂的不依从比例分别为14.4%、25.9%和43.6%。
  • 高衰弱风险评分等级与他汀类不依从相关(OR 2.29,95%CI 1.02-4.86),也与RAS抑制剂不依从相关(OR 2.06,95%CI 1.04-4.04)。
  • 合并主动脉瓣置换与他汀类不依从相关(OR 1.64,95%CI 1.11-2.38),也与RAS抑制剂不依从相关(OR 1.78,95%CI 1.26-2.52)。
  • 术后新处方某药物类别与他汀类不依从相关(OR 2.87,95%CI 2.06-4.01)、与β受体阻滞剂不依从相关(OR 1.70,95%CI 1.32-2.18)、与RAS抑制剂不依从相关(OR 6.95,95%CI 5.27-9.25)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We assessed adherence to statins, beta-blockers and renin-angiotensin system (RAS) inhibitors after coronary artery bypass graft surgery and factors associated with non-adherence. METHODS: This nationwide retrospective cohort study included all individuals undergoing coronary artery bypass surgery from 22 May 2007 to 20 December 2018, at Landspitali-the National University Hospital (n = 1536). Data on dispensed prescriptions were retrieved from the National Prescription Medicine Registry. Adherence was estimated by the proportion of days covered up to 2 years after hospital discharge, with cut-offs for strict adherence and non-adherence at over 80% and under 50%, respectively. Multivariable logistic regression was used to assess variables associated with non-adherence. RESULTS: Criteria for strict adherence were met by 39.2%, 36.9% and 30.1% of patients for statins, beta-blockers and RAS inhibitors, respectively. Non-adherence criteria were met for 14.4%, 25.9% and 43.6% of patients for statins, beta-blockers and RAS inhibitors, respectively. High Hospital Frailty Risk Score Class (statins: odds ratio (OR) 2.29, confidence interval (CI) 1.02-4.86; RAS inhibitors: OR 2.06, CI 1.04-4.04), concomitant aortic valve replacement (statins: OR 1.64, CI 1.11-2.38; RAS inhibitors: OR 1.78, CI 1.26-2.52) and a new prescription for a medication class following surgery (statins: OR 2.87, CI 2.06-4.01; beta-blockers: OR 1.70, CI 1.32-2.18; RAS inhibitors: OR 6.95, CI 5.27-9.25) were associated with non-adherence. CONCLUSIONS: Non-adherence to medical therapy after coronary artery bypass surgery is common. Patients with a higher burden of frailty and patients naive to the medical treatment of coronary artery disease should be a target group for efforts to increase medication adherence.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Heitmann LA, Gudmundsdottir IJ, Jonsdottir F, et al. A retrospective study on adherence to secondary prevention medications after coronary bypass surgery. Eur J Cardiothorac Surg. 2022. PMID: 35134874. doi:10.1093/ejcts/ezac054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。